Scorpion Therapeutics Launches With $108 Million
- Posted by ISPE Boston
- On November 5, 2020
Scorpion Therapeutics has closed a $108 million Series A financing. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver the next generation of precision oncology medicines. Scorpion will focus initially on three key efforts: designing best or first-in-class drugs against known oncogenes; drugging known – but classically undruggable – cancer targets; and discovering and rapidly drugging novel targets with the potential to transform cancer treatment paradigms.
“Cancer is a complicated and devastating disease that continues to evade our best efforts to conquer it. Precision medicine represents a tremendous advance, with the potential to offer increased efficacy and decreased toxicity, but its promise remains unfulfilled for far too many patients,” said Dr. Glick, the company’s founding president and CEO. “At Scorpion, we have assembled a world-class team to push the limits of biology, bioinformatics, and medicinal chemistry to identify and drug the most promising therapeutic targets for cancer patients. Our deep capabilities in next-generation chemistry enable us to design precision therapeutics for both new targets and those previously dismissed as undruggable. Moreover, we have assembled leaders in clinical development, with the expertise to efficiently advance our product candidates to patients. With these tools, we are building an unparalleled pipeline of small-molecule drugs to address untapped vulnerabilities in cancer and provide fresh hope to people in need.” (Source: Scorpion Therapeutics Website, 26 October, 2020)